💊 ยา A-Z 🧬 เป้าหมาย 🛠 เครื่องมือ 📚 คู่มือ
ยาทั้งหมด หมวดหมู่ยา ด้านการรักษา ผลข้างเคียง
คู่มือ อภิธานศัพท์ ไทม์ไลน์
การเปรียบเทียบ เส้นทางของยา กลุ่มยา
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Vandetanib

CHEMBL24828 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
475.4 g/mol
LogP
4.9
Phase
4

This targeted therapy blocks multiple receptors (VEGFR, EGFR, and RET) involved in tumor growth and blood vessel formation, and is used to treat symptomatic or progressive medullary thyroid cancer that cannot be surgically removed. It is taken as a daily oral tablet. It can cause a serious prolongation of the heart's electrical rhythm (QT prolongation), requiring regular heart monitoring.

น้ำหนักโมเลกุล

475.4000 g/mol

LogP

4.90

TPSA

59.50 Ų

Lipinski RO5

ผ่าน

ด้านการรักษา

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Endometriosis Benign Prostatic Hyperplasia Glaucoma Cardiovascular Disease Age-Related Macular Degeneration Neurology Psychiatry Endocrinology Respiratory Disease Dermatology Hematology Pain Management Ophthalmology Non-Small Cell Lung Cancer Rheumatoid Arthritis Osteoporosis Asthma Chronic Obstructive Pulmonary Disease Immunology Alzheimer's Disease Parkinson's Disease Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Infectious Disease Melanoma Hepatology Oncology Nephrology Gastroesophageal Reflux Disease Inflammatory Bowel Disease Psoriasis Obstetrics & Gynecology Anesthesiology Systemic Lupus Erythematosus Multiple Sclerosis Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Urology Stroke Deep Vein Thrombosis / Pulmonary Embolism Hyperlipidemia Obesity Lymphoma Gastroenterology Rheumatology Transplant Medicine Type 2 Diabetes Hypertension Major Depressive Disorder Breast Cancer Atopic Dermatitis Gout Chronic Pain Malaria HIV/AIDS Hepatitis C Tuberculosis Heart Failure Atrial Fibrillation Prostate Cancer Colorectal Cancer Leukemia

กลไกการออกฤทธิ์

Inhibits vascular endothelial growth factor (VEGF) signaling, blocking angiogenesis (new blood vessel formation) that tumors require for growth and metastasis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Inhibits vascular endothelial growth factor (VEGF) signaling, blocking angiogenesis (new blood vessel formation) that tumors require for growth and metastasis.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1

                

                

                
                

                    
InChI

                    
InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)

                

                

                

                    
                    

                        
Molecular Formula

                        
C22H24BrFN4O2

                    

                    
                    

                        
HBD / HBA

                        
1 / 7

                    

                    
                    

                        
พันธะที่หมุนได้

                        
6

                    

                    
                    
                    

                        
อะตอมหนัก

                        
30

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
คำถามที่พบบ่อย

                

                    
                    

                        
                        

                            
This targeted therapy blocks multiple receptors (VEGFR, EGFR, and RET) involved in tumor growth and blood vessel formation, and is used to treat symptomatic or progressive medullary thyroid cancer that cannot be surgically removed. It is taken as a daily oral tablet. It can cause a serious prolongation of the heart's electrical rhythm (QT prolongation), requiring regular heart monitoring.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits vascular endothelial growth factor (VEGF) signaling, blocking angiogenesis (new blood vessel formation) that tumors require for growth and metastasis.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Vandetanib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL24828.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 3081361.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
ข้อจำกัดความรับผิดชอบทางการแพทย์

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.